Skip to content

The Effect of Calcium Intake on Calcium and Bone Metabolism During Load Carriage in Women

The Effect of Calcium Intake on Calcium and Bone Metabolism During Load Carriage in Women: a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04823156
Acronym
En-Bone
Enrollment
40
Registered
2021-03-30
Start date
2022-03-24
Completion date
2023-05-19
Last updated
2023-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calcium Deficiency

Keywords

Military, Stress Fracture, Calcium, Bone Metabolism

Brief summary

This randomised trial will investigate the effect of calcium supplementation on bone and calcium metabolism in women during acute load carriage exercise. This study will test the hypothesis that calcium supplementation before load carriage exercise will attenuate the decline in serum ionised calcium and increase in parathyroid hormone and bone resorption.

Detailed description

Endurance exercise decreases serum ionised calcium and increases parathyroid hormone and bone resorption. These disturbances to calcium homeostasis can be attenuated by calcium supplementation before exercise. Military field exercises are characterised by high exercising energy expenditures, restricted dietary intake, and prolonged periods of load carriage. These exercise and nutritional challenges can result in impaired bone turnover, a negative calcium balance, and an increased risk of stress fracture. It is unknown if military load carriage disturbs calcium homeostasis and whether calcium supplementation before exercise can attenuate this disturbance. This crossover randomised controlled trial will investigate the effect of acute calcium supplementation on bone and calcium metabolism in women during acute load carriage exercise. Each participant will complete two 2 h load carriage trials. The trials will be performed after either consuming 1000 mg of calcium one hour before or with no treatment. During each experimental trial blood and urine will be sampled for markers of bone and calcium metabolism. Primary Outcome: The absolute change in urine calcium balance (Ca44:Ca42) between pre- and post-load carriage will be compared between the non-supplemented (Control) and calcium supplemented trial (Supplement) using one-way ANCOVAs with pre-load carriage calcium balance (either as a ratio, or both the numerator and denominator) as the covariate, or a linear mixed model with the restricted maximum likelihood estimation to allow incorporation of incomplete data. Secondary Outcomes: Circulating measures of bone turnover and calcium metabolism during load carriage will be compared between Control and Supplement using linear mixed models with the restricted maximum likelihood estimation to allow incorporation of incomplete data.

Interventions

DIETARY_SUPPLEMENTCalcium

Daily calcium food supplement.

Sponsors

University of East Anglia
CollaboratorOTHER
Osteolabs, GEOMAR
CollaboratorUNKNOWN
Army Health Branch, British Army
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Masking description

Calcium supplements will be provided open-label.

Intervention model description

Crossover randomised controlled trial.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 36 Years
Healthy volunteers
Yes

Inclusion criteria

1. Female sex; 2. Aged 18 to 36 years old; 3. Maximal rate of oxygen uptake of ≥ 35 ml∙kg-1∙min-1; 4. Weight stable (no change in self-reported body mass ≥ 5% over the previous 3 months); 5. BMI between 18 and 30 kg∙m2; 6. Not pregnant.

Exclusion criteria

1. Evidence of disordered eating (≥ 20 on the EAT-26); 2. Self-reported change in body mass of ≥ 5% over the previous 3 months; 3. Vitamin D deficient (total 25(OH)D \< 30 nmol∙L-1); 4. Maximal rate of oxygen uptake of \< 35 ml∙kg-1∙min-1; 5. Total body BMD T-score of \< -1; 6. Evidence of menstrual disturbance (oligomenorrhoea: \< 9 menstrual cycles in previous 12 months or amenorrhoea: ≤ 3 menstrual cycles in the previous 12 months); 7. Pregnant; 8. Current smoker, or stopped smoking within the last three months; 9. Taking any medications known to affect bone or calcium metabolism (e.g. treatment for thyroid disorders); 10. Self-declared history of heart, liver or kidney disease, diabetes or thyroid disorder; 11. Self-reported stress fracture or any other bone injuries in the previous 12 months; 12. Anaemia (haemoglobin \<12 g∙/dL-1). 13. Currently using the implant, injection, or the progesterone-only pill ('mini pill').

Design outcomes

Primary

MeasureTime frameDescription
Change in calcium balance.Before and immediately after exercise.The ratio of the calcium isotopes Ca44:Ca42 in spot urine samples.

Secondary

MeasureTime frameDescription
Circulating calcium isotopes during load carriage.Before and immediately after exercise.The ratio of the calcium isotopes Ca44 and Ca42 (Ca44:Ca42) in blood.
Bone turnover during load carriage.0, 20, 40, 60, 80, 100, and 120 minutes during, and 15, 30, 60 and 90 minutes following, exercise.Circulating concentration of procollagen type 1 N-terminal propeptide (P1NP), beta carboxy-terminal cross-linking telopeptide of type 1 collagen (βCTX), osteocalcin, and sclerostin.
Calcium metabolism during load carriage.0, 20, 40, 60, 80, 100, and 120 minutes during, and 15, 30, 60 and 90 minutes following, exercise.Circulating concentration of ionized calcium, phosphate, and intact parathyroid hormone.
Dermal calcium loss.During exercise.Concentrations of total calcium and the ratio of the calcium isotopes Ca44 and Ca42 (Ca44:Ca42) in sweat.

Other

MeasureTime frameDescription
Change in muscle strength during load carriage.Before and immediately after exercise.Loss of muscle strength in the knee extensors and flexors measured by Biodex in response to load carriage exercise.

Countries

United Kingdom

Contacts

Primary ContactThomas J O'Leary, PhD
thomas.oleary100@mod.gov.uk
Backup ContactCharlotte V Coombs, PhD
charlotte.coombs102@mod.gov.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026